Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Nivolumab + Ipilimumab + Chemotherapy in Untreated Metastatic/Recurrent NSCLC
NCT06946797Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Sep 2025; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06946797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946797.